Pfizer And Biontech Submit Application To FDA For Emergency Use Authorization Of Omicron Ba.4/ba.5-Adapted Bivalent Covid-19 Vaccine

Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older Companies have rapidly scaled
  • Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older
  • Companies have rapidly scaled production and stand ready to deliver doses of Omicron BA.4/BA.5-adapted bivalent vaccines for September, and will begin shipping immediately pending authorization
    • Rolling submission for Omicron BA.4/BA.5-adapted bivalent vaccine to be completed with the European Medicines Agency in the coming days
Total
0
Shares
Related Posts
Read More

A Look Into Energy Sector Value Stocks

  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

CDEV